BNA会议议程——翻译后

MAIN CONFERENCE DAY ONE
Wednesday 24 Aug 2011
8:00 Registration and Morning Coffee
8:45 Conference opening remarks
8:50 Chair’s opening remarks
Simon Haworth, Founder, Team Ventures
第一天主要会议日程
8:00 登记早咖啡
8:45 会议开场白
8:50 主席开场白
Simon Haworth ，Team Ventures的创始人
Founder, Team Ventures
Simon founded Team Ventures Ltd, the European operation of BSG Team Ventures, and leads the Biotechnology and Cleantech practices for BSG Team Ventures worldwide. He also founded European early stage investor IPSO Ventures PLC and uses this experience to lead our Fundraising activities. Simon trained with Arthur Andersen in the UK, focussing on MBO and related special work and established the resea
Team Ventures的创始人
Simon创立了Team Ventures，开创了BSG Team Ventures的欧洲业务，使BSG公司因生物技术和清洁能源技术而闻名于世。

他还创立了欧洲早期阶段投资者IPSO Ventures PLC，并把该经验运用到善款筹集活动中。

西蒙和阿瑟安德森受训与英国，侧重于MBO和相关的工作，创立了…
9:00 Panel discussion: Identifying the Asian pharma industry trends and the growth potential you can capitalise on in the next 5 years
S. Venkatesh, Director, Strategy & Business Development, Pfizer
Jan-Anders Karlsson, Chief Executive Officer, S*BIO
Matthias Fehr, CFA, Investment Advisor, HBM Partners AG
Simon Haworth, Founder, Team Ventures
Stanley Chang, Chairman and Chief Executive Officer, Medigen Biotechnology
The pharma market over the world will experience significant shifts. Asia Pacific region has emerged as the fastest growing pharmaceutical market over recent years. This unique panel brings together the major players from global pharmas, Asian leading Biotechs and VCs to discuss how you can capitalise on the growth potential in the Asia Pacific market.
9:00小组讨论：确定亚洲制药行业的发展趋势和未来五年的增长潜力。

S. Venkatesh 辉瑞战略与业务发展董事
Jan-Anders Karlsson S*BIO CEO
Matthias Feh 注册金融分析师，HBM合作伙伴的投资顾问
Simon Haworth Team Ventures的创始人
Stanley Chang 基亚生物科技董事长兼CEO
世界各地的医药市场将经历重大的转变，近年来亚太地区已成为医药市场增长最快的地区。

这个独特的小组汇集了来自全球制药公司的主要参与者，亚洲领先的生物技术和VCs将就如何利用在亚太市场的增长潜力进行讨论。

∙Lessons learnt from major deals and acquisitions done in 2010 in Asia
∙Identifying what are the business growth opportunities in Asia ∙Examining what are the expected trends for the following areas for Asia:
o VC and government funding
o Partnerships
o M&A (including cross-border M&A
●从2010年在亚洲主要交易和完成的收购中学习经验教训
●确定讨论什么是亚洲的经济增长机遇
●从以下方面确定亚洲的预期趋势
风险投资和政府基金
合作伙伴关系
M&A
9:40 Identifying the roles and the potential of Public Private Partnership (PPP) in Asia
Lee Eng Hin, Executive Director, BMRC, Agency for Science, Technology and Research (A*STAR)
According to PWC’s recent report, public-private partnerships in healthcare worldwide worth US$70 trillion up to 2020. Reports have also shown an increasing trend of PPP in Asia in the last recent years. Partnerships between public and private organisations play an important role in getting new medicines from “bench to bedside” by speeding up the translation of basic research into real applications. In this session we bring Prof Lee of A*STAR, Singapore’s leading agency for fostering world-class scientific research to discuss the potential of PPP in Asia.
9:40确定Public Private Partnership (PPP)在亚洲的角色和潜力。

Lee Eng Hin，BMRC，科研机构，技术和研究中心的执行董事
根据PWC的最新报告，到2020年公私关系在全球医疗中价值70亿美金。

报告同样表明，在过去的近几年中PPP在亚洲的增长趋势。

公营和私营的合作关系在从“实验到临床”中获取新药物时扮演重要的作用，这种关系通过加速转换基础研究到实际应用来实现的。

在本次会议中，我们带来了Lee教授的A*STAR，新加坡领导机构为促进世界水平的科研讨论PPP在亚洲的潜力。

Lee Eng Hin
Executive Director, BMRC, Agency for Science, Technology and Research (A*STAR)
Dr Lee is currently the Executive Director of the Biomedical Research Council, Agency for Science, Technology and Research, Singapore. He holds a concurrent appointment as Professor of Orthopaedic Surgery at the National University of Singapore. He was a past Dean of the Faculty of Medicine, National University of Singapore. He is currently a Senior Consultant in Orthopaedic Surgery at the Nationa Lee Eng Hin生物医学研究理事会，科学，技术和研究局的执行董事
Dr Lee是新加坡生物医学研究理事会，科学，技术和研究局的现任董事，同时他还兼任新加坡国立大学矫形外科教授一职，他是前任新加坡国立大学医学院院长，目前他是矫形外科高级顾问…
10:10 Panel discussion: Identifying Asia as a potential licensing partner
10:10小组讨论：确定亚洲作为一个潜在的可允许的合作伙伴。

Roger Hill, Executive Director, Global Licensing & Business Development, Boehringer Ingelheim
Phil Kearney, Director, Licensing & External Research, Merck Sharp & Dohme
Carl Firth, Chief Executive Officer & Founder, ASLAN Pharmaceuticals
David Dally, Chief Financial Officer, MerLion Pharmaceutical
Goro Takeda, Managing Director for Asia, Sofinnova Ventures
Roger Hill, 全球认证及业务拓展的执行董事
Over 300 licensing deals, market/distribution, discovery and other deal types involving Asia Pacific-based companies and research institutes were reported between Q3 2009 and Q2 2010, and this trend will continue to grow in 2011 and beyond. In this presentation we bring key experts to discuss:
∙What are the external innovations and licensing opportunities in Asia?
∙What innovative licensing strategy works best in licensing deals with Asian partners?
∙How do you find the right development and commercialisation risk partner in Asia?
∙What are the challenges of in-licensing an Asian technology or platform?
∙Predicting the direction of licensing activities in Asia in 2012 and beyond
据2009第三季度和2010第二季度的报告显示，超过300许可协议，市场/销售，发现以及其他的交易类型涉及到亚太地区的公司和科研单位，并且这种趋势在2011年及以后还会增长。

在这种现状下，我们集合主要的专家进行如下讨论：
●什么是亚洲外部创新和认证机遇？
●在与亚洲伙伴的许可交易中，什么是最好的创新授权策略？
●如何在亚洲寻找到正确的发展和商业化的风险合作伙伴？
●在亚洲引入式授权技术或平台中的挑战是什么？
●预测2012及以后在亚洲许可证贸易活动的方向。

10:50 Morning networking break and to view exhibitions
11:30 Identifying the opportunities for pharmaceutical R&D innovation and partnership in Asia Roger Hill, Executive Director, Global Licensing & Business Development, Boehringer Ingelheim Western drug companies who are now struggling with expiring patents have added a sense of urgency searching for partners in Asia. In addition a dwindling pipeline of new drugs and burgeoning costs have made them look to Asia's vast markets for new ideas, partnerships and customers. In this session, Roger will discuss:
∙An overview of partnerships forged between MNCs and local biotech and research institutions
∙The business/partnership models being deployed in Asia
∙Insights into deal making between biotech and big pharma
∙Risk sharing with Asian partners
10:50 上午互联网工作中场休息、观展
11:30 确定在亚洲医药研发创新和合作关系
Roger Hill，勃林格殷格翰全球许可及业务发展执行董事，一家专利即将到期西方制药公司，已经意识到急迫感，正在积极寻找亚洲合作伙伴。

此外，新药物来源的萎缩和高成本迫使他们把眼光放到了广阔的亚洲市场去寻找新的思路，合作伙伴和客户。

这本次会议，Roger将会讨论：
●伪造的跨国公司和当地生物技术和研究机构之间的合作关系大的概述
●商业合作关系将会在亚洲展开
●生物技术机构和大的制药企业之间从洞察到成交
●和亚洲合作伙伴分担风险
Roger Hill
Executive Director, Global Licensing & Business Development, Boehringer Ingelheim
As Executive Director & Head, Global Licensing - Commercial Opportunities, Dr. Hill's responsibilities include identifying and executing Business Development & Licensing opportunities that enable Boehringer-Ingelheim's Prescription Medicine and CHC franchises in both mature and emerging markets. Following extensive
Therapeutic Area R&D experiences at
●Roger Hill勃林格殷格翰全球许可及业务发展执行董事
●做为执行董事和领导，全球的许可及商业机遇
●Dr. Hill的职责是确定和执行，使勃林格殷格翰公司的处方药和文化委员会
的专营权在成熟和新兴市场的业务发展。

12:00 Panel discussion: Bridging the cultural divide in global partnerships – how can this lead to an effective deal making business spectrum between East-West?
Roger Hill, Executive Director, Global Licensing & Business Development, Boehringer Ingelheim Wu Ke, President and Founder, Shanghai BravoBio
Simon Haworth, Founder, Team Ventures
Stanley Chang, Chairman and Chief Executive Officer, Medigen Biotechnology
Adelene Q. Perkins, President and Chief Executive Officer , Infinity Pharmaceuticals
12:00小组讨论：弥合全球关系的文化鸿沟，如何能在促进中西方商务往来中得到有效的处理？
Foreign companies seeking partnerships in Asia are often unprepared to handle a wide range of cultural and organisational differences presented in Asia. This unique panel brings together both international and local players to discuss their offerings and how they are looking to solve partnership gaps.
∙Identifying what skills rather than technology that western companies can bring to Asia
∙What appetite is there for Asian companies to partner with western counterparts?
∙What can the East bring to the West in a partnering deal and vice versa
∙What are the lessons learned regarding negotiating and managing East-West partnering deals?
在亚洲寻求合作关系外国公司通常对较大的文化和组织上的差异毫无准备，这个独特的小组汇集了全球和本地的成员来讨论他们的产品以及如何解决合作关系上的鸿沟。

●讨论西方公司能给亚洲带来什么样的技巧而不是技术
●对亚洲公司来说与西方同行合作的动力是什么？
●东方公司能给西方公司带来什么？反之亦然。

●关于从东西方合作协议的谈判和管理中得到的教训是什么？
12:40 Networking lunch
Peter Cichon, Regional Strategic Development Manager, Bayerhealthcare
Pharmaceuticals
Mark McHale, Chief Scientific Officer, ASLAN Pharmaceuticals
Sanjay Sehgal, Managing Partner & CEO, East West Capital Partners ∙Topical roundtable: M&A and joint venture discussion
∙Roundtable head: Peter Cichon, Regional Strategic Development Manager, Bayerhealthcare Pharmaceuticals
∙Topical roundtable: Future licensing trends discussion
∙Topical roundtable: R&D innovation and partnership discussion
∙Roundtable head: Mark McHale, Chief Scientific Officer, ASLAN Pharmaceuticals
∙Topical roundtable: Valuation, funding and investment trends discussion
∙Roundtable head: Sanjay Sehgal, Managing Partner & CEO, East West Capital Partners
12:40 午餐
●专题圆桌会议：并购和合资讨论
●圆桌会议主持：Peter Cichon，Bayerhealthcare Pharmaceuticals区域战略发
展经理
●圆桌会主题：未来发牌趋势讨论
●圆桌会主题：研发创新和合作关系讨论
●圆桌会主持：Mark McHale，Chief Scientific Officer, ASLAN
Pharmaceuticals
●圆桌会主题：股价、基金和投资趋势讨论
●圆桌会主持：Sanjay Sehgal, Managing Partner & CEO, East West Capital
Partners
14:10 Chair’s opening remarks
Simon Haworth, Founder, Team Ventures
14:10 主席开场白
Simon Haworth, Team Ventures创始人
14:20 Identifying the emerging trends in global pharma – Cross border alliances with Indian generic companies
S. Venkatesh, Director, Strategy & Business Development, Pfizer
India and China are all set to dominate the global generic (off-patent drugs) market as low manufacturing and R&D cost would prompt key pharma players to set up their base here. It further said that generics have not only reached a critical scale of USD 100-billion in size but also achieved penetration in several key markets across the globe and have garnered a significant share of the prescription volume thus indicating that generics would grab a dominant pie of the overall global pharma market in the next few years. This session will discuss:
∙Evolving Global Pharma Industry (Growth dwindling in developed markets, pricing pressures from healthcare/ reimbursement authorities) ∙Attractiveness of rapidly growing Emerging markets in context of global slowdown
∙Increasing focus on Emerging markets like India by Global pharma
∙Greater openness to explore different markets (generics), different alliance models
14:20 确定全球制药的新趋势——与印度仿制药公司的跨境联盟。

S. Venkatesh，辉瑞公司战略与发展部执行董事
印度和中国在全球的仿制药（非专利）药市场占有主导地位，因其较低的生产和
S. Venkatesh
Director, Strategy & Business Development, Pfizer
Venkatesh handles Strategy and Business development at Pfizer. He has an extensive experience of over 18 years in multiple industries (pharmaceuticals, consumer products) and multiple functions (marketing, business development and commercial operations). Venkatesh has worked in organizations like P&G, Dr Reddys and Zydus
Cadila prior to Pfizer.Venkatesh is an Engineering graduate.
S. Venkatesh 辉瑞战略及业务发展董事
Venkatesh主要负责辉瑞的战略及业务发展，他拥有超过18年的丰富经验，在多个行业（医药，消费类产品）和拥有多种才能（营销，业务开发和商业化运作）。

Venkatesh在去辉瑞前曾在宝洁，Dr Reddys and Zydus Cadila等工作过，而他是一个工程学本科生。

14:50 Panel discussion: Determining the opportunities in early stage investing in Asia Jan-Anders Karlsson, Chief Executive Officer, S*BIO
Yi Shi, Managing Director, Lilly Asian Ventures
Goro Takeda, Managing Director for Asia, Sofinnova Ventures
Matthias Fehr, CFA, Investment Advisor, HBM Partners AG
Damien Lim, General Partner, BioVeda Capital
Sanjay Sehgal, Managing Partner & CEO, East West Capital Partners
14:50小组讨论：确定在亚洲投资的早期阶段的机遇
In the past, it has been a relatively slow process for investors to inject capital in early stage companies. However in recent years in Asia, this trend has been changing, with more domestic investors and more VC funds being established to focus on early stage investing. This session will look at the new financing models currently being used in the pharma industry.
∙Examining the current and future trends in early stage investing in Asia
∙Assessing what are the government initiatives to encourage early stage developments and funding
∙Identifying what areas of biotech in Asia will VCs invest
∙Examining if there is any successful investment models in Asia for adoption to maximise ROI
15:30 Feedback from lunch and champagne roundtable heads
Peter Cichon, Regional Strategic Development Manager, Bayerhealthcare Pharmaceuticals
Mark McHale, Chief Scientific Officer, ASLAN Pharmaceuticals
Sanjay Sehgal, Managing Partner & CEO, East West Capital Partners
In this session each of the roundtable heads will brief delegates on the main findings
15:30圆桌首脑会议及意见反馈（含午餐和香槟）
15:45 Afternoon break
16:15 Investing in a partnership: Learning from the Merck approach
Phil Kearney, Director, Licensing & External Research, Merck Sharp & Dohme
These days, everyone seems to be talking about joint venture partnerships, yet there is little definition surrounding what joint ventures are and how you can make them work for you. In this presentation, Phil will share his insights on what this will mean for a successful partnership.
∙Examining what are the types of relationships involved in a collaboration
∙Successful strategy for gaining big business – stimulating partnership starting with small to bigger deals
∙Case study on public–private partnership in Asia – what are the pros and cons? 15:45 下午间休
16:15 学习默克方法投资合作关系
Phil Kearney
Director, Licensing & External Research, Merck Sharp & Dohme
Dr Phil Kearney joined Merck Sharp & Dohme Australia in 2007 as the key scout for innovative research and development in Australia, New Zealand and some parts of South East Asia. The Sydney-born scientist has the challenge of uncovering and commercializing discoveries by local researchers that have strong potential to benefit the health of people around the globe. Prior to joining
Phil Kearney
Dr Phil Kearney 于2007年加入默沙东澳大利亚区，主要在澳大利亚，新西兰和部分东南亚国家从事创新性研发。

这个在悉尼出生的科学家致力于开发并产业化当地研发人员具有较强潜力的发现，以造福与全球人类健康。

16:45 The perfect pitch - local biotech investment challenge
Yi Shi, Managing Director, Lilly Asian Ventures
Matthias Fehr, CFA, Investment Advisor, HBM Partners AG
Patrick Doyle, President, Business & Corporate, Kareus Therapeutics SA
Adelene Q. Perkins, President and Chief Executive Officer , Infinity Pharmaceuticals Roger Edwards, Chief Exceutive Officer, Neural Diagnostics
In this groundbreaking session, 3 local biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners as well as to our panel of experts.
16:45完美的间距- 当地的生物技术投资的挑战
在这一开创性的会议，3位当地的生化公司将会有机会向我们这些潜在合作的观众以及我们的专家小组展示他们的“完美的间距”。

16.45-17.00 Biotech #1 Presentation - Patrick Doyle, President, Business & Corporate, Kareus Therapeutics
17.00-17.15 Biotech #2 Presentation - Adelene Q. Perkins, President and Chief Executive Officer, Infinity Pharmaceuticals
17.15-17.30 Biotech #3 Presentation - Roger Edwards, Chief Executive Officer, Neural Diagnostics
17.30-17.50 Feedback from our panel of judges
17:50 Award ceremony for the perfect pitch followed by the chair’s closing remarks
18:00 Networking Reception and BioNetwork Asia Dinner
20:00 End
16:45-17:00 生物#1简报- Patrick Doyle，
17:00-17:15生物#2简报—Adelene Q. Perkins, Infinity Pharmaceuticals 总裁兼CEO
17.15-17.30生物#3简报Roger Edwards, Chief Executive Officer, Neural Diagnostics
17.30-17.50 评审团的反馈
17:50 主席致闭幕词以及颁奖仪式
18:00 交流酒会和BioNetwork Asia晚宴
20:00 结束。

MAIN CONFERENCE DAY TWO
Thursday 25 Aug 2011
8:00 Registration and Morning Coffee
8:50 Chair’s opening remarks
Simon Haworth, Founder, Team Ventures
9:00 Keynote address: Identifying successful strategies and business planning techniques for M&A in Asia
Shakil Ohara, Business Strategy Director, Pacific, Asia, Abbott Nutritions
第二天会议日程
2011/8/25 星期四
8:00 登记早咖啡
8:50 主席开场白
Simon Haworth, Founder, Team Ventures
9:00主题演讲：识别M＆A在亚洲成功的战略和业务规划技术
Shakil Ohara 雅培亚太地区商务战略董事
Expanding healthcare coverage in emerging Asia-Pacific markets and rapid economic growth are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 "patent cliff" and slowing growth in major western developed markets. As these markets develop, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region. In this presentation, Shakil who is an expert in M&A transactions and has also acquired Hokuriku Seiyaku, a Pharma company listed on Tokyo Stock Exchange to discuss:
∙Assessing valuation of a target, financing the deal and key contract issues in M&A deal flow
∙Analysis of the healthcare buy-out trends, drivers and current financing
∙Identifying and assessing the right partners for partnership
∙Challenges in acquiring a turn-around in Asia and managing post-merger integration
交易专家同时收购了在东京证交所上市的制药公司Hokuriku Seiyaku，将讨论到：
●
●
●
●
Shakil Ohara
Business Strategy Director, Pacific, Asia, Abbott Nutritions
Shakil Ohara is currently Business Strategy Director for Abbott Nutrition covering Pacific Asia. He has over 25 years’ experience in banking, investment, and health care spread over three geographies,that is,India, Japan, and Singapore. During his career he has handled many M&A transactions as well as development of strategic partnerships. During his tenure with Abbott in Japan
9:30 Panel discussion: Examining what are the biotech innovations that are coming out of Asia in the next 5 years
Muhammad Tani bin Tabin, Senior Vice President, Exploit Technologies Madhukumar M. K, Head of Business Operations, Stempeutics
Shermal Perera, Founder and Managing Director, SIOGEN Biotech
Simon Haworth, Founder, Team Ventures
Brian Lam, Director for Business Development, Inviragen
9:30小组讨论：亚洲未来5年内的生物技术创新
Things are looking pretty bleak right now especially with the expiring patents of western pharma companies. But as the saying goes, necessity is the mother of invention. Pharma research is increasing in Asia and the western companies are looking in this market for new innovations to increase the productivity of their pipelines. In this session, we bring experts from the biotechs to discuss: ∙What type of innovations do biotech firms have in their development pipeline?
∙How are Asian’s biotech innovations consistent with the large pharma companies’ pipeline strategies?
∙Predicting the time scale these innovations are to be launched
∙Are biotech firms in Asia sufficient to fill this gap of innovations?
∙What are the advantages of launching low margin products like vaccine?
∙What roles can government funded research play to fill this gap in innovations?
∙Are Asian governments’ funded biotech innovations consistent with the large pharma companies’ pipeline strategies?
事情看起来相当的暗淡，特别是与西方制药公司的专利到期。

俗话说，必要性是创新之母，制药公司在亚洲的研发实力一直在增加，西方制药公司也在这个市场寻找创新以增加生产线的生产力。

在本次会议中，我们将组织来自生化公司的专家进行如下讨论：
●生物技术公司在其发展中是一个什么样的创新类型
●亚洲的生化公司是如何做到与大型的制药公司的生产战略一致
●预测这些创新公司将会举办的时间尺度
●在亚洲的这些生化公司是否不足以弥补创新的差距
●开展低毛利产品比如疫苗的优势是什么
●政府资助的研究中在填补创新差距中发挥什么样的作用
●亚洲各国政府资助的生化技术创新是否与大型的医药集团的发展战略一
致？
10:10 Understanding the latest pricing and reimbursement (P&R) mechanisms in Asia for effective business strategies
Abdulkadir Keskinaslan, Pricing Director, AMAC and China, Global Pricing & Market Access, Novartis Pharma AG
International drug developers need to prioritise P&R as an important factor in drug development. The governments in Asia especially China and India are reducing their reimbursement fund and place more control on the pricing of the drug. This session will discuss:
∙Identifying the growing unmet need for patient access: budget constraints and pressure for a broader and improved access
∙What are the trends in pricing and use of health technology assessment for reimbursement decision making?
Examining the opportunities for ensuring broader patient access in Asia
10:10 为了了解有效的业务战略，需要了解亚洲最新的定价和报销机制。

●辨识病人救治项目不断增加的的未满足的需要：预算限制和压力将限制其扩
大和改善。

●在定价和报销决策卫生技术评估的发展趋势是什么？
●确保病人在亚洲获得更多的机会
Abdulkadir Keskinaslan,Pricing Director, AMAC and China, Global Pricing & Market Access, Novartis Pharma AG
Abdulkadir Keskinaslan, MD, MBA, MPH is Pricing Director for the Asia-Pacific, Middle East and African Countries at Novartis Pharma AG, Basel, Switzerland; leading price implementation for the whole Novartis portfolio in his region. Dr. Keskinaslan gained his Medical Degree from Cerraphasa School of Medicine, Istanbul University, Turkey, and went on to complete his residency training in Family Med
Abdulkadir Keskinaslan
Abdulkadir
10:40 Morning networking break
11:10 Panel discussion: Partnerships for early stage innovations that are government funded – a blessing or a curse?
Carl Firth, Chief Executive Officer & Founder, ASLAN Pharmaceuticals Madhukumar M. K, Head of Business Operations, Stempeutics
Shermal Perera, Founder and Managing Director, SIOGEN Biotech
Patrick Doyle, President, Business & Corporate, Kareus Therapeutics SA Jayabaskar Thiyagarajan, Assistant Director (Strategic Programmes) , National Medical Research Council
In recent years, government initiatives are on the increase in emerging Asian markets to encourage early stage innovation research. But will there be any “strings attached” for such government funded project? In this session, we bring experts to debate: ∙What money is available from governments in the region and what strings are attached?
∙What are the pros and cons of accepting government financing?
∙What are the implications for subsequent rounds of financing?
∙Is equity-based financing better than grants or debt?
11:10 小组讨论：由政府资助的早期阶段的创新的合作关系是福还是祸？
●什么钱可以从各地政府中得到，而附加条件是什么？
●接受政府融资的利弊是什么？
●随后几轮融资的影响是什么/
●股权融资优于赠款或债务?
11:50 Case Study: Identifying the market access strategies in Asia - Diversity & Challenge
Geoffrey Whitehead, Export Manager APAC, Douglas Pharmaceuticals
The uncertain economic situation is the most pressing challenge for the pharma industry in Asia. According to Cegedim’s recent report, the top two key barriers to market access success are difficulty in identifying market access stakeholders and lack of ROI information. In this presentation, Geoffrey from Douglas Pharmaceuticals,
one of the fastest growing pharmaceutical companies in Australasia, will share his insights to improve your market access strategies which are critical to your future success.
∙Identifying what are the factors that contribute to identifying markets of opportunity
∙Aligning therapy focus to the opportunity- What are some of the challenges- Identifying successful market entry strategies for adoption to maximse ROI-
Examining the trend of transferring or selling an IP – what are the pros and
cons?
11:50案例分析：确定在亚洲的市场准入战略- 多样性与挑战性
Geoffrey Whitehead，Douglas Pharmaceuticals出口部经理，
最近的报告中，
影响市场准入的成功前两个障碍是难以确定市场准入的利益相关者和缺乏投资回报率信息。

在本次演示中，Geoffrey来自Douglas Pharmaceuticals，做为在大洋洲制药企业中增长最快的企业之一。

将分享他的见解，以促进对你未来成功至关重要的市场准入战略。

确定哪些因素有助于确定市场的机会
面对机会时确定哪些是挑战
确定通过成功的市场准入战略最大化投资回报率
检验转让和售出IP，其趋势，利弊是什么？
Export Manager APAC, Douglas Pharmaceuticals
As a seasoned professional, Geoff has significant hands on understanding of the APAC markets. With over 20 years of Asia experience, Geoff brings insights and expertise to business partnerships and has a deep understanding of the growth and development needs for each unique geography. With a career summary including, Business Unit Head for Novo Nordisk Australia Biopharmaceuticals, General Manager
做为一个经验丰富的专业人士，Geoff对亚太市场有着实际意义的理解，拥有20多年的亚洲市场经验，Geoff把自己的简介和专业知识运用到商业合作关系中，
12:20 Identifying the new landscape of Good’s Manufacturing Practice (GMP) regulations in China
Wu Ke, President and Founder, Shanghai BravoBio
China's new GMP regulation was implemented on March 1, 2011 to improve the quality of manufactured drugs. As elevated standards under the new GMP mean
higher manufacturing costs for drug companies. How will the new regulation has an impact on the pharma industry especially the smaller companies? We have invited Wu Ke, founder of a newborn biotech who brings with him 23 years of experiences in biopharma industry to discuss:
∙The Chinese GMP versus Western GMP – what are the differences in the requirements and how does it influence the general GMP compliance ∙What changes will the new Chinese GMP regulations bring to the local pharmaceutical industry?
∙What are the main differences with the old guidelines; are there still some differences to Western guidelines?
12:20 确定在中国新的GMP下的景观。

他是一项新的生物技术的创始人，这项技术使得他在生化制药行业拥有了23年的经验。

●中国的GMP和西方的GMP相比—在要求上有什么区别以及它是如何影响
一般的GMP认证的？
●新的中国GMP给当地的制药行业带来的变化是什么？
●和旧准则相比，主要的区别是什么，与西方的相比是否存在差异？
President and Founder, Shanghai BravoBio
Dr. Wu Ke is the President and Founder of Shanghai BravoBio Co., Ltd. He has 23 years of experiences in biopharm industry and had successfully developed 7 products being approved by SFDA and marketed in China. Dr. Wu Ke was Executive President of Shanghai Zerun Biotechnology Co., Ltd., in charge of management of QA/QC, Manufacture, Engineering and Maintenance, Regulatory Affairs, Marketing and Sal
Dr. Wu Ke是Shanghai BravoBio Co., Ltd
12:50 Networking lunch
12:50 午餐时间
14:10 Panel discussion: Examining a new model for sharing risks and reaping rewards Brian Lam, Director for Business Development, Inviragen
Geoffrey Whitehead, Export Manager APAC, Douglas Pharmaceuticals
Roger Edwards, Chief Exceutive Officer, Neural Diagnostics
The need for drug companies to cut costs, driven by a generally tougher business environment, is made worse by cut-throat competition. New approach and models are needed especially in such intense industry competition and high costs and risks, pharma companies can no longer support the old way of keeping large teams of
in-house researchers and waiting for results. In this session, we have invited experts to share what are the partnering-risk sharing models for your effective partnerships.
∙Understanding how is success measured
∙Identifying how do these sharing models work
∙Examining how is IP protection being ensured
14:10小组讨论：确定一个新的风险共担和激励奖励的模式
●了解成功是如何衡量的
●识别这些共享模型是如何运作的
●检查是如何确保知识产权保护
14:50 Panel discussion: How can the industry make the most out of relationships with academia in Asia?
Simon Haworth, Founder, Team Ventures
Syed Aljunid, Senior Scientist, United Nations University- International Institute for Global Health
Lye Whye-Kei, Director, Business Development (Future Health Care), Nanyang Technological University
Irene Cheong, Director, Industry Liaison Office, National University of Singapore
Enterprise
While funding for academic research in the US and EU is either holding steady or declining, Asia is growing its academic research funding budgets exponentially. In China for example, research outfits with academics are increasingly seen by western pharmaceutical giants as ideal working partners. This opens some new and interesting possibilities for the life science industry to partner with academic researchers in these countries. In this session, we bring experts to highlight:
∙Recent developments in the Asian academic and government sector life science R&D
∙The pros and cons of establishing partnerships with these institutions
∙What are some of the innovative financial/collaboration/business models whereby these arrangements can be facilitated?
∙What are the legal considerations of partnering with academia?
14:50小组讨论：行业如何才能与亚洲学术界保持最好的关系？
在美国和欧盟的学术研究经费是保持稳定或下降同时，亚洲的学术研究拨款预算却在成倍增长。

例如在中国，学者的研究著作在西方国家看来可以看到较快的增长，这些学者可以做为他们理想的工作伙伴。

与这些国家的科研机构合作将为生命科学行业展开新的更有吸引力的可能。

在本次会议中，我们将邀请专家强调：
●
●
●
●
15.30 Chair's closing remarks
15:40 Afternoon break
16:10 End of BioNetwork Asia 2011
15:30 主席闭幕词
15:40下午中场休息
16:10 2011 BioNetwork Asia结束。